Expression of the Mismatch Repair Gene hMLH1 Is Enhanced in Non-Small Cell Lung Cancer with EGFR Mutations

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Li, Mei ^a   Zhang, Qiuping ^a   Liu, Lina ^a   Lu, Weipeng ^a   Wei, Hong ^a   Li, Rachel W ^b   Lu, Shen ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; MISMATCH REPAIR PROTEIN; PROTEIN MLH1; PROTEIN MSH2; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; RAS PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; EXON; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; MLH1 GENE; ONCOGENE K RAS; PROTEIN EXPRESSION; BASE MISPAIRING; DNA REPAIR; GENETICS; LUNG TUMOR; MIDDLE AGED; NON SMALL CELL LUNG CANCER; VERY ELDERLY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BASE PAIR MISMATCH; CARCINOMA, NON-SMALL-CELL LUNG; DNA MISMATCH REPAIR; DNA REPAIR; EXONS; FEMALE; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84886256194     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078500     Document Type: Article

References (47)

1. Shigematsu H, Gazdar AF, (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118: 257-262. doi:10.1002/ijc.21496. PubMed: 16231326.
2. Sholl LM, Xiao Y, Joshi V, Yeap BY, Cioffredi LA, et al. (2010) EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol 133: 922-934. doi:10.1309/AJCPST1CTHZS3PSZ. PubMed: 20472851.
3. Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, et al. (2010) Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 5: 1734-1740. doi:10.1097/JTO.0b013e3181f0beca. PubMed: 20881644.
4. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, et al. (2009) EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 15: 4554-4560. doi:10.1158/1078-0432.CCR-09-0089. PubMed: 19584155.
5. Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, et al. (2010) Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 46: 1997-2009. doi:10.1016/j.ejca.2010.03.036. PubMed: 20413299.
6. Yamaguchi F, Kugawa S, Tateno H, Kokubu F, Fukuchi K, (2012) Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy. Lung Cancer 78: 201-206. doi:10.1016/j.lungcan.2012.08.014. PubMed: 23026641.
7. Pu X, Hildebrandt MA, Lu C, Lin J, Stewart DJ, et al. (2011) PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer 71: 82-88. doi:10.1016/j.lungcan.2010.04.008. PubMed: 20447721.
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139. doi:10.1056/NEJMoa040938. PubMed: 15118073.
9. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, et al. (2007) KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13: 2890-2896. doi:10.1158/1078-0432.CCR-06-3043. PubMed: 17504988.
10. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500. doi:10.1126/science.1099314. PubMed: 15118125.
11. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLOS Med 2: e73. doi:10.1371/journal.pmed.0020073. PubMed: 15737014.
12. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, et al. (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12: 6494-6501. doi:10.1158/1078-0432.CCR-06-1570. PubMed: 17085664.
13. Shah SN, Hile SE, Eckert KA, (2010) Defective mismatch repair, microsatellite mutation bias, and variability in clinical cancer phenotypes. Cancer Res 70: 431-435. doi:10.1158/1538-7445.AM10-431. PubMed: 20068152.
14. Lujan SA, Williams JS, Pursell ZF, Abdulovic-Cui AA, Clark AB, et al. (2012) Mismatch repair balances leading and lagging strand DNA replication fidelity. PLOS Genet 8: e1003016. PubMed: 23071460.
15. Poulogiannis G, Frayling IM, Arends MJ, (2010) DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology 56: 167-179. doi:10.1111/j.1365-2559.2009.03392.x. PubMed: 20102395.
16. Stoehr C, Burger M, Stoehr R, Bertz S, Ruemmele P, et al. (2012) Mismatch repair proteins hMLH1 and hMSH2 are differently expressed in the three main subtypes of sporadic renal cell carcinoma. Pathobiology 79: 162-168. doi:10.1159/000335642. PubMed: 22378480.
17. van Puijenbroek M, Middeldorp A, Tops CM, van Eijk R, van der Klift HM, et al. (2008) Genome-wide copy neutral LOH is infrequent in familial and sporadic microsatellite unstable carcinomas. Fam Cancer 7: 319-330. doi:10.1007/s10689-008-9194-8. PubMed: 18415027.
18. Bischoff J, Ignatov A, Semczuk A, Schwarzenau C, Ignatov T, et al. (2012) hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases. Clin Exp Metastasis, 29: 889-900. PubMed: 22552371.
19. Donehower LA, Creighton CJ, Schultz N, Shinbrot E, Chang K, et al. (2012) MLH1-Silenced and Non-Silenced Subgroups of Hypermutated Colorectal Carcinomas Have Distinct Mutational Landscapes. J Pathol, 229: 99-110. PubMed: 22899370.
20. Kawaguchi M, Yanokura M, Banno K, Kobayashi Y, Kuwabara Y, et al. (2009) Analysis of a correlation between the BRAF V600E mutation and abnormal DNA mismatch repair in patients with sporadic endometrial cancer. Int J Oncol 34: 1541-1547. PubMed: 19424571.
21. Chung H, Young DJ, Lopez CG, Le TA, Lee JK, et al. (2008) Mutation rates of TGFBR2 and ACVR2 coding microsatellites in human cells with defective DNA mismatch repair. PLOS ONE 3: e3463. doi:10.1371/journal.pone.0003463. PubMed: 18941508.
22. Lüchtenborg M, Weijenberg MP, Wark PA, Saritas AM, Roemen GM, et al. (2005) Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study. BMC Cancer 5: 160. doi:10.1186/1471-2407-5-160. PubMed: 16356174.
23. Li M, Liu L, Wang Z, Wang L, Liu Z, et al. (2008) Overexpression of hMSH2 and hMLH1 protein in certain gastric cancers and their surrounding mucosae. Oncol Rep 19: 401-406. PubMed: 18202787.
24. Scartozzi M, Franciosi V, Campanini N, Benedetti G, Barbieri F, et al. (2006) Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. Lung Cancer 53: 103-109. doi:10.1016/j.lungcan.2006.03.008. PubMed: 16716446.
25. Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, et al. (2006) Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst 98: 396-406. doi:10.1093/jnci/djj093. PubMed: 16537832.
26. Takahashi Y, Kondo K, Hirose T, Nakagawa H, Tsuyuguchi M, et al. (2005) Microsatellite instability and protein expression of the DNA mismatch repair gene, hMLH1, of lung cancer in chromate-exposed workers. Mol Carcinog 42: 150-158. doi:10.1002/mc.20073. PubMed: 15605365.
27. Xinarianos G, Liloglou T, Prime W, Maloney P, Callaghan J, et al. (2000) hMLH1 and hMSH2 expression correlates with allelic imbalance on chromosome 3p in non-small cell lung carcinomas. Cancer Res 60: 4216-4221. PubMed: 10945633.
28. Kouso H, Yoshino I, Miura N, Takenaka T, Ohba T, et al. (2008) Expression of mismatch repair proteins, hMLH1/hMSH2, in non-small cell lung cancer tissues and its clinical significance. J Surg Oncol 98: 377-383. doi:10.1002/jso.21108. PubMed: 18646042.
29. Li M, Liu L, Liu Z, Yue S, Zhou L, et al. (2009) The status of KRAS mutations in patients with non-small cell lung cancers from mainland China. Oncol Rep 22: 1013-1020. PubMed: 19787214.
30. Li M, Zhang Q, Liu L, Liu Z, Zhou L, et al. (2011) The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China. Neoplasma 58: 74-81. doi:10.4149/neo_2011_01_74. PubMed: 21067269.
31. Betz BL, Roh MH, Weigelin HC, Placido JB, Schmidt LA, et al. (2011) The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. Am J Clin Pathol 136: 564-571. doi:10.1309/AJCP84TUTQOSUONG. PubMed: 21917678.
32. Wu CC, Hsu HY, Liu HP, Chang JW, Chen YT, et al. (2008) Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer 113: 3199-3208. doi:10.1002/cncr.23925. PubMed: 18932251.
33. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967. doi:10.1056/NEJMoa0904554. PubMed: 19692684.
34. Sasaki H, Endo K, Takada M, Kawahara M, Kitahara N, et al. (2006) L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer. Lung Cancer 54: 103-108. doi:10.1016/j.lungcan.2006.06.003. PubMed: 16890322.
35. Lo FY, Chang JW, Chang IS, Chen YJ, Hsu HS, et al. (2012) The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization. BMC Cancer 12: 235. doi:10.1186/1471-2407-12-235. PubMed: 22691236.
36. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346. doi:10.1093/jnci/dji055. PubMed: 15741570.
37. Vageli D, Daniil Z, Dahabreh J, Karagianni E, Vamvakopoulou DN, et al. (2009) Phenotypic mismatch repair hMSH2 and hMLH1 gene expression profiles in primary non-small cell lung carcinomas. Lung Cancer 64: 282-288. doi:10.1016/j.lungcan.2008.09.018. PubMed: 19056144.
38. Vageli DP, Zaravinos A, Daniil Z, Dahabreh J, Doukas SG, et al. (2012) hMSH2 and hMLH1 gene expression patterns differ between lung adenocarcinoma and squamous cell carcinoma: correlation with patient survival and response to adjuvant chemotherapy treatment. Int J Biol Markers: 0: e400-4. PubMed: 22865300.
39. Wang YC, Lu YP, Tseng RC, Lin RK, Chang JW, et al. (2003) Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest 111: 887-895. doi:10.1172/JCI15475. PubMed: 12639995.
40. Saletta F, Matullo G, Manuguerra M, Arena S, Bardelli A, et al. (2007) Exposure to the tobacco smoke constituent 4-aminobiphenyl induces chromosomal instability in human cancer cells. Cancer Res 67: 7088-7094. doi:10.1158/0008-5472.CAN-06-4420. PubMed: 17671175.
41. Vogelsang M, Wang Y, Veber N, Mwapagha LM, Parker MI, (2012) The cumulative effects of polymorphisms in the DNA mismatch repair genes and tobacco smoking in oesophageal cancer risk. PLOS ONE 7: e36962. doi:10.1371/journal.pone.0036962. PubMed: 22623965.
42. Nielsen FC, Jäger AC, Lützen A, Bundgaard JR, Rasmussen LJ, (2004) Characterization of human exonuclease 1 in complex with mismatch repair proteins, subcellular localization and association with PCNA. Oncogene 23: 1457-1468. doi:10.1038/sj.onc.1207265. PubMed: 14676842.
43. Romeo F, Falbo L, Di Sanzo M, Misaggi R, Faniello MC, et al. (2011) BRCA1 is required for hMLH1 stabilization following doxorubicin-induced DNA damage. Int J Biochem Cell Biol 43: 1754-1763. doi:10.1016/j.biocel.2011.08.011. PubMed: 21864706.
44. Stubbert LJ, Smith JM, McKay BC, (2010) Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin. BMC Cancer 10: 207. doi:10.1186/1471-2407-10-207. PubMed: 20470425.
45. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, et al. (2000) BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 14: 927-939. PubMed: 10783165.
46. An Y, Jin G, Wang H, Wang Y, Liu H, et al. (2008) Polymorphisms in hMLH1 and risk of early-onset lung cancer in a southeast Chinese population. Lung Cancer 59: 164-170. doi:10.1016/j.lungcan.2007.08.003. PubMed: 17870204.
47. Shih CM, Chen CY, Lee IH, Kao WT, Wang YC, (2010) A polymorphism in the hMLH1 gene (-93G--A) associated with lung cancer susceptibility and prognosis. Int J Mol Med 25: 165-170. PubMed: 19956916.